Pacemaker implantation due to cardiac conduction disease in patients with subsequent cardiac sarcoidosis may be a marker of early disease and is associated with adverse 5-year clinical outcome

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Anna Slattman

Skane University Hospital, Lund (Sweden)

7 More presentations in this session

Presentation thumbnail

Results of permanent lead implantation at the His bundle without the use of an electrophysiological unit

Associate Professor C. Israel (Bielefeld, DE)

Abstract Slides

Presentation thumbnail

Patient reported symptoms in emergency health care service in patients with complete atrioventricular block

Doctor C. Bang (Soeborg, DK)

Abstract Slides

Presentation thumbnail

Etiologies and predictors for cardiac implantable electronic device implantation in young patients hospitalized for complete atrioventricular block

Doctor G. Margolis (Hadera, IL)

Abstract Slides

Presentation thumbnail

Type 2 diabetes is associated with higher risk of 3rd degree atrioventricular block: a Danish nationwide registry study

Doctor S. Haxha (Lund, SE)

Abstract Slides

Presentation thumbnail

A novel scoring system to predict cardiac device implantation in patients presenting with syncope

Doctor A. Khan (Birmingham, GB)

Abstract Slides

Access the full session

Session thumbnail

Evaluation and treatment of conduction disease in 2022

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Congress Presentation

My most difficult surface ECG

Congress Presentation

How to manage patients with bradycardic phenotype: pace or ablate or...?

Congress Presentation

Detection of prolonged atrioventricular conduction and AVNRT following dual-chamber pacemaker implantation in sick sinus syndrome

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources